baber/WOPTO huggingface dataset:
Patent JP-2002510398-A (JP)
Title: ２軸ジャイロスコープ
IPC: G01C19/5677
Filed: 1999-03-10
Abstract: (57)【要約】
２軸ジャイロスコープは、実質的にリング又はフープ様形状の構造物を有する実質的に平坦な振動共振器（５）と、共振器（５）をＣｏｓｎθ平面外搬送波モードで振動させるための搬送波モード駆動手段（７）であって、ｎは２又はそれ以上の整数値である搬送波モード駆動手段（７）と、共振器（５）を可撓的に支持するための支持手段（６）と、共振器（５）の平面外運動を検知するための搬送波モードピックオフ手段（８）と、Ｘ軸を中心にしたジャイロスコープの回転にレスポンスした共振器の平面内Ｃｏｓｎ 1 θレスポンスモード運動を検知するためのＸ軸レスポンスモードピックオフ手段（９）であって、ｎ 1 は、ｎ＋１又はｎ−１の値であるＸ軸レスポンスモードピックオフ手段（９）と、Ｙ軸を中心にしたジャイロスコープの回転にレスポンスした共振器（５）の平面内Ｓｉｎｎ 1 θレスポンスモード運動を検知するためのＹ軸レスポンスモードピックオフ手段（１１）であって、ｎ 1 は、ｎ＋１又はｎ−１の値であって、Ｘ軸レスポンスモードのものと同一であるＹ軸レスポンスモードピックオフ手段（１１）とを有する。
Patent MX-160662-A (MX)
Inventor: PALL DAVID B
IPC: D04H1/56
Filed: 1984-12-31
Abstract: Cylindrical fibrous structures comprising a fibrous mass of nonwoven, synthetic, polymeric microfibers wherein the microfibers are substantially free of fiber-to-fiber bonding and secured to each other by mechanical entanglement or intertwining, the fiber structure having a substantially constant voids volume over at least a substantial portion of the structure and, preferably, a graded fiber diameter structure, both as measured in the radial direction. The structures are particularly useful as depth filters.The method for preparing such fibrous structures comprises the steps of:(a) extruding synthetic, polymeric material from a fiberizing die and attenuating the extruded polymeric material to form microfibers by the application of one or more gas streams directed toward a rotating mandrel and a forming roll in operative relationship with the mandrel;(b) cooling the synthetic, polymeric microfibers prior to their collection on the mandrel to a temperature below that at which they bond or fuse together, thereby substantially eliminating fiber-to-fiber bonding; and(c) collecting the cooled microfibers on the mandrel as a nonwoven, synthetic fibrous mass while applying a force on the exterior surface of the collected microfibers by the forming roll; wherein the process variables are controlled to form the cylindrical fiber structure with at least the major portion of the fibrous mass having a substantially constant voids volume.
Patent NZ-226751-A (NZ)
Title: Peptide-oligonucleotide conjugate probe and its method of production, detection of specific nucleotide sequence
Inventor: HARALAMBIDIS JIM
IPC: C12Q1/68
Filed: 1988-10-27
Abstract: Oligonucleotide-polyamide conjugates of the formula X-L-Y, where X is a polyamide, Y is an oligonucleotide, and L is a linker which forms a covalent bond with the amino-terminus of the polyamide X and the 3' phosphate group of the oligonucleotide Y. Conjugates may be synthesized by assembling a polyamide on a solid support matrix, adding a suitable linker molecule, followed by synthesis of the oligonucleotide. Methods for detecting specific polynucleotides with oligonucleotide-polyamide conjugates are also described. <IMAGE>
Patent NZ-228893-A (NZ)
Title: Substituted quinoline and naphthyridine derivatives and pharmaceutical compositions
Inventor: ISAO HAYAKAWA
IPC: C07D/
Filed: 1989-04-26
Abstract: N1-(1,2-cis-2-halogenocydopropyl)-substituted pyridonecarboxylic acid derivatives represented by formula (I) and the salts thereof are disclosed. These compounds have patent antibacterial activities against a wide variety of infectious bacteria, and are useful as antibacterial agents by oral or parenteral administration. <CHEM>
Patent NZ-239864-A (NZ)
Title: 1-aryl-3-pyridinyl-2-propene-1-ones and pharmaceutical compositions
Inventor: DINERSTEIN ROBERT JOSEPH
IPC: A61P29/00
Filed: 1991-09-19
Abstract: This invention relates to 1-aryl-3-pyridinyl-2-propene-1-ones and pharmaceutical compositions containing these compounds as active ingredients useful as calcium uptake inhibitors in leukocytes and thrombocytes and the process of their preparation.
Patent NZ-241546-A (NZ)
Title: N-substituted quinoline and cinnoline derivatives, preparation and pharmaceutical compositions thereof
Inventor: CLEMENCE FRANCOIS
IPC: C07D215/233
Filed: 1992-02-07
Abstract: Product of formula (ID): <IMAGE>  in which: <IMAGE>     D1, D2, D3 and D4 nitrogen, methine or methylene,   R1B hydrogen, alkyl, alkenyl, alkynyl, acyl, cyano or carboxy,   RB, R2B and R3B:   a) hydrogen, halogen, hydroxyl, mercapto, cyano, nitro, sulpho, formyl, benzoyl, acyl, carboxy or cycloalkyl,   b) alkyl, alkenyl, alkynyl, alkyloxy, alkylthio,   c) aryl, arylalkyl, arylalkenyl, aryloxy or arylthio   d) <IMAGE>     R5B alkylene,   YB represents -Y1B-B-Y2B:   Y1B represents aryl   B represents:   either a single bond between Y1B and Y2B,   or: -CO-, -NH-CO-, -CO-NH-, -O-(CH2)n- or -S-(CH2)n- (n = 0 to 4),   Y2B represents: either, if B represents a single bond, hydrogen, halogen, hydroxyl, cyano, nitro, trifluoromethyl, carboxy, tetrazole or isoxazole,   or, irrespective of the nature of B, Y1B.   These products justify their use as pharmaceuticals.
Patent NZ-244339-A (NZ)
Title: Electrode for electrolytic cell
Inventor: TENFAELT MIKAEL
IPC: C25C7/02
Filed: 1992-09-15
Abstract: The invention relates to an electrode for electrolysis, whose front side comprises a plurality of substantially parallel channels (2) defined by substantially parallel threads (1) of electrically conducting material, which are attached to and in electric contact with the underlying electrode structure (10, 11, 12). Moreover, the invention relates to a method of producing an electrode, an electrolytic cell comprising an electrode according to the invention, and the use of such an electrode in electrolysis. <IMAGE>
Patent NZ-262996-A (NZ)
Title: Phosphonomethyldipeptides and pharmaceutical compositions
Inventor: D ORCHYMONT HUGUES
IPC: A61P43/00
Filed: 1994-02-22
Abstract: Dipeptides and analogs thereof having a phosphonomethyl moiety attached thereto which inhibit Endothelin Converting Enzyme and are thus useful in treating conditions responsive thereto.
Patent NZ-264065-A (NZ)
Title: Selection marker gene free recombinant microorganism strains and their preparation
Inventor: SELTEN GERARDUS CORNELIUS MARI
IPC: C12N15/52
Filed: 1994-07-22
Abstract: The present invention discloses a selection marker free system which can be used to introduce genetic modifications in bacteria, yeasts and fungi. The system can be employed to introduce or delete desired genes or DNA fragments in the genome of the indicated host species without leaving any undesired DNA i.e. the selection marker used for selection of transformants or other DNA used for cloning. In this way strains have been developed containing only desired genes introduced at desired chromosomal sites. Similarly, desired DNA fragments have been deleted or replaced at desired sites.
Patent NZ-270134-A (NZ)
Title: Medicaments containing 2-methylamino-2-phenylcyclohexanone (mpch) for immunomodulation and treating infection
Inventor: PREISS DETLEF
IPC: A61K31/135
Filed: 1994-12-14
Abstract: This invention relates to the use of 2-methylamino-2-phenylcyclohexanone and of pharmaceuticals which contain this active agent in combination with physiologically acceptable solid or liquid supporting materials or diluents for treating bacterial, fungal, virus or protozoan infections as well as for immunomodulation.
Patent NZ-297015-A (NZ)
Title: Dialkyl(c1-c6)-ketone peroxide containing compositions; use for preserving organic tissues
Inventor: COLLADO JUAN JIMENEZ
IPC: A01N1/00
Filed: 1995-12-19
Abstract: The compositions for the preservation of organic tissues are comprised of a mixture from 12 to 70 % of at least one dialkyl (C1-C6)-ketone peroxide, from 10 to 15 % of glycerine, from 10 to 70 % of at least one alcohol and, optionally, from 0 to 10 % of a complementary marking, coloring and/or aromatic agent. Said compositions may be mixed with other appropriate agents or diluents, and can be applied especially to the preservation of tissues of all types, of human or origin, preferably by embalming or immersion.
Patent NZ-310076-A (NZ)
Title: Face valve apparatus for continuous motion can decorator
Inventor: WILLIAMS ROBERT
IPC: F16K11/074
Filed: 1996-06-05
Abstract: Face valve apparatus having a plurality of valve stations each of which includes a replaceable pad that is behind and in contact with a planar face of a continuously moving valve section having a plurality of inlet ports in a circular array about a rotational axis for the movable valve section. Each of the valve stations are removably mounted to a fixed support by a plurality of fasteners that are accessible for operation from behind the support. Each pad defines an inlet port disposed in front of said support and operatively positioned so that for part of each revolution fo the movable valve section, each of the inlet ports communicates directly with the outlet port. When operation of certain of the fasteners releases a selected valve station from the fixed support, the selected valve station is removable from the support through an opening therein so that the pad is rearward of the support, where such pad is accessible for replacement without disturbing mounting of any of the other valve stations to the fixed support.
Patent NZ-314147-A (NZ)
Title: Ostomy system includes a pouch with a resealable coupling adhesive and a body-side mounting wafer with a releasable film and support therefor
Inventor: KUCZYNSKI THOMAS J
IPC: A61F5/443
Filed: 1997-01-29
Abstract: Ostomy pouch comprises pouch envelope formed of flexible plastic material defining waste collection chamber for body waste that passes through a stoma; waste inlet opening formed in the envelope for positioning around stoma to permit passage of waste material from the stoma to the collection chamber; and flexible annular pouch coupling mechanism on the pouch envelope at the waste inlet opening. An ostomy pouch (12) comprises a pouch envelope (16) formed of flexible plastic material defining a waste collection chamber for body waste that passes through a stoma (120); waste inlet opening (32) formed in the envelope for positioning around the stoma to permit passage of waste material from the stoma to the collection chamber; and flexible annular pouch coupling mechanism on the pouch envelope at the waste inlet opening. The coupling mechanism has a resealable coupling adhesive and support for the resealable adhesive for avoiding wrinkling of the resealable coupling adhesive when the coupling mechanism is flexed or separated from a coupling bond with a body-side mounting wafer (14), the support including a foam layer joined to an outside surface of the pouch envelope. An independent claim is also included for a body-side mounting wafer comprising multi-layer assembly having an opening for a stoma, and having a biocompatible adhesive layer on one side for securement to a body surface around the stoma, and an opposite side with a release film for detachable engagement with a pouch to be mounted on the wafer, the assembly further including support for the release film for avoiding wrinkling of the release film when the release film is flexed or is separated from a coupling bond with the pouch.
Patent NZ-316288-A (NZ)
Title: 3,4-dihydro-isoquinoline, 4,5-3H-benzo[c]azepin-7-ol and 1H-isoindole derivatives and pharmaceutical compositions containing them
Inventor: THOMAS CRAIG E
IPC: A61K31/473
Filed: 1996-08-15
Abstract: he application is directed to cyclic nitrones of the formula (I) in which R1 and R2 are each independently represented by a C1-3 alkyl or R1 and R2 together form a C5-6 alkylene ring or a ring of structure (a), Z represents (CHx)n, wherein x and n are independently 0 or an integer from 1-2; R3 is represented by a substituent selected from the group consisting of hydrogen, C1-4 alkyl, OH, OAc or (b); and the ring represented by X is a substituent selected from the group consisting of (c), (d), (e) or (f) wherein the area of dark shading represents the side of attachment to the nitrone ring, R4, R5, R6 and R7 are independently selected from the group consisting of hydrogen, C1-3 alkyl, OH or C1-3 alkoxy and the pharmaceutically acceptable salts thereof, with the proviso that when R1 and R2 together form a C5-6 alkylene ring and n is 1, then R3 cannot be hydrogen and their use in the prevention of oxidation tissue damage by free radicals, their use in the treatment of a number of disease states in which radicals either damage or destroy tissues via oxidation, and pharmaceutical compositions containing these cyclic nitrones.
Patent NZ-332862-A (NZ)
Title: Balloon catheter for photoactive therapy with extended irradiation window
Inventor: OVERHOLT BERGEIN F
IPC: A61F2/958
Filed: 1997-05-07
Abstract: A balloon catheter for use in photodynamic therapy (PDT) has a treatment window which is at least 4cm in length.  Light may be delivered to the treatment window by an LED or by an optical fibre and diffuser.  This arrangement is stated to provide uniform illumination in a single effective dose to a biological column such as the oesophagus.
Patent NZ-333147-A (NZ)
Title: Process for producing polymers from phenolic or aromatic amine compounds by using a enzyme and uses thereof
Inventor: ECHIGO TAKASHI
IPC: A61P31/04
Filed: 1997-05-20
Abstract: A process for macromolecularizing phenolic compounds or aromatic amine compounds by the action of a catalyst comprising an enzyme having a polyphenol oxidizing activity in the alkali region; applications of the compounds obtained by the above process to thickeners, stabilizers, coagulants, emulsifiers, dispersants, water retainers, antioxidants, adhesives, concrete admixtures, dyes, coating materials, petroleum recovering agent, soil conditioner, a blow-applied seed bearing surface soil stabilizer, deodorants, smell eliminators, agricultural chemical spreaders, feeding stuff binders, bactericides, antimicrobial agents, viral infection inhibitors, bioadhesion preventives, biotic repellents, insecticides, poultices, ink bases or wood treating agents; and method of waste water disposal, a method of deoxygenation and a method of treating wood, concrete or soil in which use is made of the above reaction.
Patent NZ-333307-A (NZ)
Title: Method for making steel in a liquid melt-fed electric furnace
Inventor: KREMER ANDRE
IPC: C21C5/52
Filed: 1997-06-10
Abstract: A method for making steel in an electric furnace, wherein a predetermined amount of liquid melt is fed into the electric furnace, is disclosed. The method comprises the steps of (a) continuously feeding a controlled flow of liquid melt into the furnace without interrupting the heating from the electric arc, (b) continuously injecting a refining gas into the furnace before the C and/or Si content of the metal bath reaches a predetermined value, until the end of the feeding process, and (c) pursuing the injection of refining gas after the predetermined amount of melt has been fed into the furnace, until the target value for the C and/or Si content of the metal bath has been reached.
Patent NZ-333574-A (NZ)
Title: Water miscible erythromycin solutions
Inventor: HOPPONEN RAYMOND E
IPC: A61K31/70
Filed: 1997-07-02
Abstract: The specification describes a stable water miscible pharmaceutical composition containing 10%-40% of erythromycin. The composition is prepared via an acetic acid reaction step to prepare a soluble erythromycin acetate.
Patent NZ-333695-A (NZ)
Title: Method for treating gastrointestinal damage with hyperimmunised milk and hyperimmunised egg
Inventor: GREENBLATT HELLEN CHAYA
IPC: A61K35/54
Filed: 1997-07-30
Abstract: A method of preventing, countering or reducing chronic gastrointestinal disorders or nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage in a non-human subject which comprises the steps of; 1. hyperimmunising an egg producing animal or a milk producing animal; and 2. administering to the subject an effective amount of hyperimmunised egg product, hyperimmunised milk product or combination thereof. Also described is the use of hyperimmunised egg and milk products in the manufacture of medicaments for the treatment of the above-mentioned disorders.
Patent NZ-335544-A (NZ)
Title: Use of GPE (tripeptide or dipeptide) in form of Gly-Pro-Glu or Gly-Pro or Pro-Glu as a neuromodulator
Inventor: GLUCKMAN PETER DAVID
IPC: A61K38/06
Filed: 1997-10-06
Abstract: A method for regulating the effects of neural enzymes by administrating an effective amount of GPE or an analogue thereof. GPE is a tripeptide consisting of amino acids Gly-Pro-Glu. Administration of GPE relates to increasing the effective amount of neural enzymes choline  acetyltransferase (ChAT), glutamic acid decarboxylase (GAD) and/or nitric oxide synthetase (NOS) in the central nervous system (CNS) for treating conditions such as motor neuron disease, Alzheimer's disease, muscular dystrophy, peripheral neuropathies, autonomic neuropathies, memory loss, neurodegeneration due to aging, post-asphyxial seizures, convulsive disorders, subarachnoid hemorrhage, transient ischemic attack, stroke, multi-infarct dementia, cerebral vasculitis or traumatic brain injury.
Patent NZ-501252-A (NZ)
Title: Gelatine encapsulated containing sertraline which exhibits conventional immediate release dosage forms, a shorter time to reach peak blood levels after oral dosing suitable for treating psychiatric and other illnesses
Inventor: CURATOLO WILLIAM JOHN
IPC: A61P3/04
Filed: 1998-06-16
Abstract: A dosage form comprising a gelatine-encapsulated composition comprising sertraline, or a pharmaceutically acceptable salt thereof, and a water-immiscible vehicle.
Patent NZ-502276-A (NZ)
Title: Polyhydroxyalkylpyrazine derivatives with D-gulose, D-galactose, D-allose, D-altrose, D-idose, D-talose, L-glucose, L-mannose, L-galactose, L-galactose, L-allose, L-altrose, L-idose, L-talose or L-gulose
Inventor: BASHIARDES GEORGES
IPC: A61K31/495
Filed: 1998-07-15
Abstract: The use of medicaments containing a compound of general formula (I) as an active ingredient in which; ·R1 represents the stereoisomer forms of the chain (II): -(CHOH)3-CH2OH and either ·R2 represents a hydrogen atom and R3 represents the stereoisomer forms of the chain (III): -CH2-(CHOH) 2-CH2OH or ·R2 represents the stereoisomer forms of chains (II): -(CHOH) 3-CH2OH or (III): -CH2-(CHOH) 2-CH2OH and ·R3 represents a hydrogen atom or a salt of such a compound with an organic or inorganic acid for the treatment and prevention of diabetes and associated complications.
Patent NZ-504818-A (NZ)
Title: Fluorimetric detection system for nucleic acids
Inventor: LEE MARTIN ALAN
IPC: C12Q1/6823
Filed: 1998-11-27
Abstract: A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising: (a) adding to a sample suspected of containing said target nucleic acid sequence, a DNA duplex binding agent, and a probe specific for said target sequence comprising a reactive molecule able to absorb fluorescence from or donate fluorescent energy to the DNA duplex binding agent, (b) subjecting the thus formed mixture to an amplification reaction in which target nucleic acid is amplified, (c) subjecting said sample to conditions under which the said probe hybridises to the target sequence, and (d) monitoring fluorescence from said sample associated with one or both of hybridisation of the probe to the target sequence and dissociation of the probe from the target sequence. This method can be used for example to monitor amplification reactions such as PCR reactions, such that the amount of target sequence present in the sample may be determined.  It may also be used to generate duplex destabilisation data such as melt hysteresis information for amplification monitoring or for detection and quantitation of polymorphisms or allelic variation, and so is useful in genetic diagnosis.
Patent NZ-505638-A (NZ)
Title: Bicyclic pyrrole derivatives as MCP-1 inhibitors
Inventor: BARKER ANDREW JOHN
IPC: C07D487/04
Filed: 1999-02-02
Abstract: Described are compounds of formula (I) or a pharmaceutically acceptable salt or ester or amide thereof, which is an inhibitor of monocyte chemoattractant protein-1, wherein, A and B together with the carbon atoms to which they are attached , form an optionally substituted 5 membered aromatic ring which includes at least one heteroatom, and X is CH2 or SO2, and R1 is an optionally substituted aryl or heteroaryl ring, and R2 is carboxy, cyano, -C(O)CH2OH, -CONHR4, -SO2NHR5, tetrazol-5-yl, SO3H, or a group of formula (II), wherein, R4 is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO2R9, wherein, R9 is alkyl, aryl, heteroaryl, or haloalkyl, or R4 is a group -(CHR10)r-COOH, wherein r is an integer of 1-3 and each R10 group is independently selected from hydrogen or alkyl; R5 is alkyl, optionally substituted aryl or optionally substituted heteroaryl, or a group COR6 , wherein, R6 is hydrogen, alkyl, aryl, heteroaryl or haloalkyl, and R7 and R8 are independently selected from hydrogen or alkyl, and R3 is hydrogen, a functional group as hereinbefore defined or an optionally substituted group selected from alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkoxy, arakyl, aralkyloxy or cycloalkyl.
Patent NZ-512005-A (NZ)
Title: New cancer treatments
Inventor: DALGLEISH ANGUS GEORGE
IPC: A61K47/20
Filed: 1999-12-09
Abstract: The disclosed relates to a product comprised of specific combinations of cell lines intended for use as an allogeneic immunotherapy agent for the treatment of prostate cancer in humans. The heterogeneity of the immunotherapeutic matches the heterogeneity of the antigenic profile in the target prostate cancer and immunises the recipients with many of the potential TAA and TSA which are expressed at various stages of the disease. Also disclosed is a vaccine comprising a combination of three different cell lines prepared from primary or metastatic prostate cancer biopsy material. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent.
Patent NZ-512849-A (NZ)
Title: Pre-conditioning against cell death
Inventor: TREMBLAY JOHANNE
IPC: A61K35/14
Filed: 2000-01-11
Abstract: Use of an aliquot of blood from the mammalian body that has been extracted therefrom and reacted ex vivo with at least one stressor selected from the group consisting of a temperature above or below body temperature, ultraviolet light, and an oxidative environment in the manufacture of a medicament.  The medicament is useful in alleviating or protecting against the symptoms of a medical disorder involving accelerated rates of apoptosis or necrosis in a mammalian body, said disorder being selected from radiation exposure disorders; chemical exposure and ingestion disorders; neurological disorders; and physical trauma disorders; through reducing the rate of or susceptibility to apoptosis or necrosis of tissues and organs of the mammalian body.
Patent NZ-515743-A (NZ)
Title: Novel naphthalene ureas as glucose uptake enhancers
Inventor: SPEVAK WAYNE
IPC: C07C309/51
Filed: 2000-05-25
Abstract: A compound of formula I, wherein: R1 and R2 are independently selected from -SO2NR72, -C(O)NR72, -NR7SO2R7, -NR7C(O)R7, -SO2OR7, -C(O)OR7, -OSO2R7, or -OC(O)R7, R5 and R6 are independently hydrogen, alkyl, cyano, halo, nitro, -SR8, -C(O)R8, -SO2OR8, -OSO2R8, -SO2NR82, -NR8SO2R8, -OC(O)R8, -C(O)OR8, -C(O)NR82, -NR8C(O)R8, -OR8, or -NR82, Y is independently alkyl, cyano, halo, nitro, -SR, -OR, or -NR2, x is independently 0, 1 or 2, and the linker is a heteroatom-containing chain described herein. The compounds are used in the manufacture of medicaments for the treatment of hyperglycemia, type I diabetes and type II diabetes.